Atsena Therapeutics announced in a press release that the FDA granted its gene therapy product candidate, ATSN-201, the regenerative medicine advanced therapy (RMAT) designation to treat X-linked ...

As part of its five-year strategic plan, Prevent Blindness has promoted five individuals to further the organization’s mission. Prevent Blindness has promoted five leaders to further its efforts and ...

Aviceda Therapeutics recently appointed Jeffrey Nau, PhD, MMS, as chief executive officer. Nau comes to Aviceda with more than 20 years of experience leading and expanding biotechnology and ...

VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME). Vantage ...

A new study found that an artificial intelligence reading label system improves ophthalmologists' diagnostic accuracy for retinal diseases and could be valuable in future medical education. A new ...

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Pykus Therapeutics announced it has completed enrollment in its pilot study, PYK-2101-RD00, evaluating PYK-2101, a focal hydrogel retinal sealant, in patients undergoing surgery for detached retina.

A team of Chinese researchers reported that fasting C-peptide (FCP) has a complicated relationship with the development of diabetic retinopathy (DR). Below a specific threshold, FCP exerts a ...

Novelty Nobility, a Korean antibody drug discovery company, recently announced it has been selected to join JLABS Korea. 1 JLABS, part of Johnson & Johnson’s global incubator network, supports ...

Opus Genetics issued a press release today announcing the 1-month open-label phase 1/2 results from the first pediatric patients treated with its investigational gene therapy candidate, OPGx-LCA5, for ...